<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ustekinumab (including biosimilars): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ustekinumab (including biosimilars): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ustekinumab (including biosimilars): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9514" href="/d/html/9514.html" rel="external">see "Ustekinumab (including biosimilars): Drug information"</a> and <a class="drug drug_patient" data-topicid="12204" href="/d/html/12204.html" rel="external">see "Ustekinumab (including biosimilars): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9419532"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Stelara</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869013"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Stelara</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F49238411"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antipsoriatic Agent</span>;</li>
<li>
<span class="list-set-name">Interleukin-12 Inhibitor</span>;</li>
<li>
<span class="list-set-name">Interleukin-23 Inhibitor</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F46146609"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing presented in mg/<b>kg</b> and fixed mg; use extra precaution to ensure dosing units.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24007983-cae4-4767-9c7c-c43cad836484">Inflammatory bowel disease, moderate to severe; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Inflammatory bowel disease, moderate to severe; refractory:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26854655','lexi-content-ref-31058718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26854655','lexi-content-ref-31058718'])">Ref</a></span>): <b>Note:</b> Dosing varies by route of administration (IV or SUBQ); use extra caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;55 kg: IV: 260 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥55 to 85 kg: IV: 390 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;85 kg: IV: 520 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i> SUBQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on retrospective studies and case reports. A retrospective study of 52 adolescent and young adult (&lt;21 years) patients (median: 16.8 years; 38 patients &lt;18 years of age) diagnosed with inflammatory bowel disease (n=42 Crohn disease; n=10 ulcerative colitis or unspecified) with a majority (81%) having failed previous tumor necrosis factor (TNF)-modulator therapy, utilized a single-dose weight-based IV induction protocol of ustekinumab in most patients (47/52, 90%); the other subjects (5) received subcutaneous induction prior to availability of IV product. Following induction, all patients received fixed dose (regardless of weight) SUBQ maintenance therapy (90 mg every 8 weeks). Results showed at the end of 52 weeks, 58% of patients had achieved steroid-free remission and 65% had achieved clinical remission. At week 52, of the 39 patients who continued on ustekinumab, 62% of patients required dosing every 4 to 7 weeks to maintain remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31058718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31058718'])">Ref</a></span>). In a retrospective case series, 4 patients (ages 12 to 17 years) who had failed or unable to tolerate previous TNF modifiers received subcutaneous induction doses of 90 mg every 4 weeks for 2 doses, followed by 90 mg every 8 weeks. Two patients were able to wean off steroid regimens and had clinical improvement and 2 patients were unresponsive to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26854655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26854655'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46fc9b4b-22ea-4096-b090-0ebc9997e04a">Plaque psoriasis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: SUBQ: Initial: 0.75 mg/<b>kg</b> at 0 and 4 weeks, followed by maintenance dose of 0.75 mg/<b>kg </b>every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 to ≤100 kg: SUBQ: Initial: 45 mg at 0 and 4 weeks, followed by maintenance dose of 45 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 kg: SUBQ: Initial: 90 mg at 0 and 4 weeks, followed by maintenance dose of 90 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">≤100 kg: SUBQ: Initial: 45 mg at 0 and 4 weeks, followed by maintenance dose of 45 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 kg: SUBQ: Initial: 90 mg at 0 and 4 weeks, followed by maintenance dose of 90 mg every 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c541f39-e6c5-46d4-8527-7742c7654e39">Psoriatic arthritis, active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis, active:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: SUBQ: Initial: 0.75 mg/<b>kg</b> at 0 and 4 weeks, followed by maintenance dose of 0.75 mg/<b>kg</b> every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 kg: SUBQ: Initial: 45 mg at 0 and 4 weeks, followed by maintenance dose of 45 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 kg and moderate to severe plaque psoriasis comorbidity: SUBQ: Initial: 90 mg at 0 and 4 weeks, followed by maintenance dose of 90 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Initial: 45 mg at 0 and 4 weeks, followed by maintenance dose of 45 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate to severe plaque psoriasis comorbidity and weight &gt;100 kg:</i> SUBQ: Initial: 90 mg at 0 and 4 weeks, followed by maintenance dose of 90 mg every 12 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193134"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51193135"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F6868014"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9514" href="/d/html/9514.html" rel="external">see "Ustekinumab (including biosimilars): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Prior to initiation, certain assessments (clinical and laboratory) are <b>required</b> with documentation and ensure age-appropriate vaccinations <b>are</b> up to date. In general, live vaccines should not be administered within 4 weeks prior to starting therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>). Refer to institutional protocols for vaccination and monitoring requirements prior to initiating therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59567581-c67d-4a97-908a-59b5a164c324">Crohn disease, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as an initial biologic agent for patients with nonfistulizing disease <b>or</b> as second-line therapy for patients who have not responded to other biologic agents (with or without fistulizing disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-35691323','lexi-content-ref-35604382','lexi-content-ref-34688373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-35691323','lexi-content-ref-35604382','lexi-content-ref-34688373'])">Ref</a></span>). Data are limited for use in postoperative maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fleshner.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fleshner.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Induction of remission:</b></p>
<p style="text-indent:-2em;margin-left:8em;">≤55 kg: <b>IV:</b> 260 mg as single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;55 kg to 85 kg: <b>IV: </b>390 mg as single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;85 kg: <b>IV: </b>520 mg as single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance of remission:</b>
<b>SUBQ:</b> 90 mg every 8 weeks starting 8 weeks after the IV induction dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959607','lexi-content-ref-23075178','lexi-content-ref-35691323','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Incomplete response or nonresponse to induction therapy (off-label dosing): </i></b> If limited or no improvement in clinical symptoms and biomarkers of disease activity (eg, C-reactive protein [CRP] and fecal calprotectin) 12 weeks after induction (4 weeks after first maintenance dose), decrease maintenance dosing interval to every 4 weeks. If inadequate response after an additional 8 to 12 weeks of every 4-week therapy, switch to alternative therapy. May switch to an alternative agent sooner than 8 to 12 weeks if disease activity is severe and symptom control is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-33133239','lexi-content-ref-36191274','lexi-content-ref-34628078','lexi-content-ref-32109634','lexi-content-ref-36930430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-33133239','lexi-content-ref-36191274','lexi-content-ref-34628078','lexi-content-ref-32109634','lexi-content-ref-36930430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Relapse while on maintenance therapy (off-label dosing)</i>:</b> For patients with initial response who have symptomatic relapse while on maintenance therapy, consider decreasing dosing interval to every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33133239','lexi-content-ref-36191274','lexi-content-ref-34628078','lexi-content-ref-32109634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33133239','lexi-content-ref-36191274','lexi-content-ref-34628078','lexi-content-ref-32109634'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7894142-6d94-43a4-8b99-5c603895aa0c">Hidradenitis suppurativa, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">≤100 kg: <b>SUBQ: </b>45 mg at 0 and 4 weeks, and then every 12 weeks thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30872149','lexi-content-ref-26641739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30872149','lexi-content-ref-26641739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;100 kg: <b>SUBQ:</b> 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30872149','lexi-content-ref-26641739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30872149','lexi-content-ref-26641739'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial and maintenance:</i></p>
<p style="text-indent:-2em;margin-left:6em;">≤100 kg: <b>SUBQ: </b>45 mg at 0 and 4 weeks, and then 45 mg every 12 weeks thereafter. <b>Note: </b>Some patients may require doses of 90 mg or maintenance dosing every 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 kg: <b>SUBQ: </b>90 mg at 0 and 4 weeks, and then 90 mg every 12 weeks thereafter. <b>Note:</b> Some patients may require maintenance dosing every 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tapering schedule (off-label):</i> Tapering approach may vary, and should be based on patient-specific factors; an example tapering schedule is provided below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36472386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36472386'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Ustekinumab Tapering Schedule for Plaque Psoriasis<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Current dosing schedule</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>New dosing schedule<sup>b</sup></b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a </sup>van der Schoot 2022</p>
<p style="text-indent:0em;">
<sup>b </sup>If disease activity increases, return to previously effective dosing schedule.</p>
<p style="text-indent:0em;">
<sup>c </sup>Optional dosing schedules.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Every 12 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Every 15 weeks<sup>c</sup> or every 18 weeks</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Every 15 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Every 18 weeks</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Every 18 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Every 21 weeks<sup>c</sup> or every 24 weeks</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Every 21 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 weeks</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b>
<b>Note:</b> May be administered alone or in combination with methotrexate.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial and maintenance: <b>SUBQ: </b>45 mg at 0 and 4 weeks, and then 45 mg every 12 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">Coexistent psoriatic arthritis and moderate to severe plaque psoriasis in patients &gt;100 kg: Initial and maintenance: <b>SUBQ: </b>90 mg at 0 and 4 weeks, and then 90 mg every 12 weeks thereafter. <b>Note: </b>Some patients may require maintenance dosing every 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28590e42-e7f9-435a-976a-9ca55340b4d3">Ulcerative colitis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction of remission:</b></p>
<p style="text-indent:-2em;margin-left:6em;">≤55 kg: <b>IV:</b> 260 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;55 kg to 85 kg:<b> IV:</b> 390 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;85 kg: <b>IV:</b> 520 mg as single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of remission:</b>
<b>SUBQ:</b> 90 mg every 8 weeks starting 8 weeks after the IV induction dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33860795','lexi-content-ref-36930430','lexi-content-ref-33086438','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33860795','lexi-content-ref-36930430','lexi-content-ref-33086438','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Inadequate primary response (off-label dosing):</i></b>If limited or no improvement in clinical symptoms and biomarkers of disease activity (eg, C-reactive protein [CRP] and fecal calprotectin) 12 weeks after induction (~4 weeks after first maintenance dose), decrease maintenance dosing interval to every 4 to 6 weeks. If inadequate response after an additional 8 to 12 weeks of every 4- to 6-week dosing, switch to alternative therapy. May switch to an alternative agent sooner than 8 to 12 weeks if disease activity is severe and symptom control is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-Cohen.1','lexi-content-ref-33775893','lexi-content-ref-36930430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-Cohen.1','lexi-content-ref-33775893','lexi-content-ref-36930430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Relapse while on maintenance therapy (off-label dosing)</i>:</b> For patients with symptomatic relapse while on maintenance therapy, consider decreasing dosing interval to every 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33775893','lexi-content-ref-36930430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33775893','lexi-content-ref-36930430'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991801"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989076"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F58898147"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions have been reported, including <b>anaphylaxis </b>and <b>infusion-related reaction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34720823','lexi-content-ref-37168900','lexi-content-ref-32588044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34720823','lexi-content-ref-37168900','lexi-content-ref-32588044'])">Ref</a></span>). Delayed reactions have also been reported, including <b>bullous pemphigoid</b>, <b>hypersensitivity angiitis</b>, <b>eczematous rash</b>, morphea, and <b>psoriasiform eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36369405','lexi-content-ref-35694729','lexi-content-ref-34309516','lexi-content-ref-34939919','lexi-content-ref-33307146','lexi-content-ref-22911203','lexi-content-ref-35789168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36369405','lexi-content-ref-35694729','lexi-content-ref-34309516','lexi-content-ref-34939919','lexi-content-ref-33307146','lexi-content-ref-22911203','lexi-content-ref-35789168'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Anaphylaxis: Non–dose-related; immunologic (ie, IgE mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34720823','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34720823','lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion-related reactions: Unknown; possibly related to release of cytokines, complement activation, degranulation of mast cells and basophils (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Non–dose-related; immunologic (ie, involving a T-cell–mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Psoriasiform eruptions: Non–dose-related; possibly related to cytokine imbalance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34309516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34309516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infusion-related reactions: Rapid; during the infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37200724','lexi-content-ref-37168900','lexi-content-ref-32588044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37200724','lexi-content-ref-37168900','lexi-content-ref-32588044'])">Ref</a></span>). Infusion reactions occur most commonly during the first infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32588044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32588044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Psoriasiform eruptions: Delayed; usually within 3 months of initiation but have been reported after 15 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33307146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33307146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IV route of administration: Some patients have developed immediate reactions following IV ustekinumab but subsequently have tolerated SUBQ ustekinumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33016326','lexi-content-ref-32904020','lexi-content-ref-37200724','lexi-content-ref-37168900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33016326','lexi-content-ref-32904020','lexi-content-ref-37200724','lexi-content-ref-37168900'])">Ref</a></span>). It has been hypothesized that EDTA, contained in the IV formulation but not the SUBQ formulation, may be responsible for reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37168900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37168900'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab may increase the risk for <b>infection</b>, including <b>serious infection</b> requiring hospitalization, or reactivation of latent infection. Serious bacterial, mycobacterial, fungal, and viral infections have been observed with use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; due to the role of the interleukin (IL)-12/IL-23 pathway in protecting the host from pathogens, ustekinumab may result in unintended downstream consequences, such as the development of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35860015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35860015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of chronic, latent, or recurrent infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent glucocorticoid or immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23192911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23192911'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic deficiency in IL-12/IL-23; in patients with IL-12/IL-23 genetic deficiencies, there is a theoretical increased risk of disseminated infection from mycobacteria, <i>Salmonella</i>, and BCG vaccinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541488'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab may increase the risk for malignancy; although, data are conflicting. Cases of rapidly appearing <b>cutaneous squamous cell carcinoma in situ</b> have been reported in patients receiving ustekinumab with preexisting risk factors for developing nonmelanoma skin cancer. However, multiple studies have shown no association between ustekinumab and malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36068977','lexi-content-ref-28893407','lexi-content-ref-21978572','lexi-content-ref-35191100','lexi-content-ref-35262671','lexi-content-ref-32964215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36068977','lexi-content-ref-28893407','lexi-content-ref-21978572','lexi-content-ref-35191100','lexi-content-ref-35262671','lexi-content-ref-32964215'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; interleukin (IL)-12 and IL-23 have been suggested to play a role in tumor immunity, but increased risk of malignancy has not been reported in IL-12 or IL-23 genetically deficient patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21978572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21978572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients &gt;60 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• History of prolonged immunosuppressant therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a history of psoralen plus ultraviolet-A radiation treatment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Noninfectious pneumonia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab use has been associated with the development of clinically serious noninfectious pneumonia, including cases of <b>cryptogenic organizing pneumonia</b>, <b>eosinophilic pneumonitis</b>, and <b>interstitial lung disease</b>, some leading to respiratory failure and prolonged hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30540343','lexi-content-ref-35854305','lexi-content-ref-32962463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30540343','lexi-content-ref-35854305','lexi-content-ref-32962463'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; may represent hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30540343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30540343'])">Ref</a></span>). One report speculates that the inhibitory effect on interleukin (IL)-12 and IL-23 may impede T-helper cells Th1 and Th17 activity to initiate a Th2-dominant response and trigger the onset of eosinophilic pneumonitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23728153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23728153'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur after 1 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30540343','lexi-content-ref-35854305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30540343','lexi-content-ref-35854305'])">Ref</a></span>); but may also occur later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32962463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32962463'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Posterior reversible encephalopathy syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab has been associated with <b>reversible posterior leukoencephalopathy syndrome</b>; signs and symptoms may include altered mental status, confusion, headaches, seizures, visual disturbances, and imaging changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36212237','lexi-content-ref-35237349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36212237','lexi-content-ref-35237349'])">Ref</a></span>). Cases were reversible with discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; possible genetic predisposition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35237349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35237349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur within a few days to several months after initiation but may also occur after a year or more (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36212237','lexi-content-ref-35237349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36212237','lexi-content-ref-35237349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36212237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36212237'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunosuppressive medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36212237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36212237'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adult and pediatric patients treated with ustekinumab may be at risk for <b>tuberculosis </b>(TB), including active and reactivated TB. Overall, a low rate of TB has been reported with ustekinumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35860015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35860015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; due to the role of the interleukin (IL)-12/IL-23 pathway in protecting the host from pathogens, ustekinumab may result in unintended downstream consequences, such as the development of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35860015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35860015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with inborn errors of IL-12/IL-23 (disseminated infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35860015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35860015'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F6867984"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis/psoriatic arthritis</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Antibody development (6% to 12%; associated with reduced efficacy in psoriasis patients)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (27%; serious infection: 0.3%)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Ustekinumab: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ustekinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious: 0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious: 0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (2%), skin carcinoma (nonmelanoma: 2%, including cutaneous squamous cell carcinoma in situ)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Malignant neoplasm (excluding nonmelanoma: 2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Erythema at injection site (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Depression (1%), dizziness (2%), fatigue (3%), headache (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (3%), back pain (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Pharyngolaryngeal pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Cellulitis</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diverticulitis of the gastrointestinal tract</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Bleeding at injection site, bruising at injection site, induration at injection site, injection-site pruritus, irritation at injection site, pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease/ulcerative colitis</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Respiratory: Nasopharyngitis (7% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acne vulgaris (1%), pruritus (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (7%), diarrhea (4%), nausea (3%), vomiting (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary tract infection (4%), vaginal mycosis (≤5%), vulvovaginal candidiasis (≤5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Antibody development (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Influenza (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Erythema at injection site (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (1%), fatigue (4%), headache (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Bronchitis (5%), sinusitis (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin carcinoma (nonmelanoma, including cutaneous squamous cell carcinoma in situ)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Malignant neoplasm (excluding nonmelanoma)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Meningitis due to Listeria monocytogenes</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Ocular herpes simplex</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abscess of rectum and/or perirectal area, appendicitis, cholecystitis, gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteomyelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Husein-ElAhmed 2022), eczematous rash (Pernet 2012), erythrodermic psoriasis (Murphy 2022), fixed drug eruption (Hafez 2020), psoriasiform eruption (Murphy 2022), pustular psoriasis (Murphy 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity angiitis (Ak 2023), infusion-related reaction (Sunny 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Atypical mycobacterial infection, bacterial infection, fungal infection (including opportunistic)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hypertension (Tan 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cryptogenic organizing pneumonia (Brinker 2019), eosinophilic pneumonitis (Kalra 2021), interstitial lung disease (Despotes 2022), lower respiratory tract infection, tuberculosis (Wang 2022)</p></div>
<div class="block coi drugH1Div" id="F6867273"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Clinically significant hypersensitivity to ustekinumab or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe infections such as sepsis, tuberculosis, and opportunistic infections</p></div>
<div class="block war drugH1Div" id="F6867274"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with ustekinumab and may be associated with loss of efficacy (AAD/NPF [Menter 2019]; Loeff 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including anaphylaxis and angioedema, has been reported. Discontinue immediately with signs/symptoms of hypersensitivity reaction and treat appropriately as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: May increase the risk for infections or reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections have been observed with use. Avoid use in patients with clinically important active infection until the infection resolves or is successfully treated. Exercise caution when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections (eg, diabetes or residence/travel from areas of endemic mycoses), with chronic, latent, or localized infections, or who are genetically deficient in IL-12/IL-23 (IL-12/IL-23 genetic deficiency may predispose patients to disseminated infection). Patients who develop a new infection while undergoing treatment should consult their health care provider and be monitored closely. If a patient develops a serious infection, therapy should be discontinued or withheld until successful resolution of infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: May increase the risk for malignancy although the impact on the development and course of malignancies is not fully defined. Rapidly appearing cutaneous squamous cell carcinomas (multiple) have been reported in patients receiving ustekinumab who were at risk for developing nonmelanoma skin cancer. Monitor all patients closely for the development of nonmelanoma skin cancer; closely follow patients &gt;60 years of age, with a history of prolonged immunosuppression, and in patients with a history of PUVA treatment. Use with caution in patients with prior malignancy (use not studied in this population).</p>
<p style="text-indent:-2em;margin-left:4em;">• Noninfectious pneumonia: Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia, some leading to respiratory failure and prolonged hospitalization, have been reported; most commonly has occurred within the first few doses. Symptoms may include cough, dyspnea, and interstitial infiltrates. Discontinue therapy and institute appropriate treatment if noninfectious pneumonia is suspected or confirmed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported. Symptoms of PRES include confusion, headache, imaging changes, seizure, and visual disturbances; most cases occur within a few days to several months after initiation of therapy but may occur ≥1 year. Monitor patients closely; discontinue therapy immediately if symptoms occur and administer appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Do not use in patients with tuberculosis (TB) disease (active TB). Patients should be evaluated for tuberculosis infection (latent TB) with a tuberculin skin test prior to starting therapy. Treatment of TB infection should be initiated before ustekinumab therapy is used. Consider antituberculosis treatment in patients with a history of tuberculosis infection or disease if an adequate prior treatment course cannot be confirmed. During and following treatment, monitor for signs/symptoms of TB disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergen immunotherapy: Use caution in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis; ustekinumab may decrease the protective effect of allergen immunotherapy, which may increase the risk of an allergic reaction to allergen immunotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppressive therapy: Use in combination with other immunosuppressive drugs during psoriasis studies has not been evaluated; use caution. Use in combination with methotrexate during psoriatic arthritis studies did not appear to affect safety or efficacy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients &gt;100 kg: May require higher dose to achieve adequate serum levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Caballero 2021; Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Although the manufacturer suggests that live vaccines should not be given concurrently, expert consensus recommends that ustekinumab be held for one dosing interval (the longest described in labeling) prior to administration of a live vaccine and then ustekinumab be held 4 weeks after administration of a live vaccine in general; individualized consideration should be given to patient risk for vaccine preventable illness and for disease flares if immunosuppressant therapy held (ACR 2022). Inactivated or nonlive vaccines may be given concurrently, but may not elicit a proper immune response. BCG vaccines should not be given 1 year prior to, during, or 1 year following treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phototherapy: Use in combination with phototherapy has not been studied; use caution.</p></div>
<div class="block prod-avail drugH1Div" id="F58811885"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Wezlana (ustekinumab-auub): FDA approved October 2023; anticipated availability January 2025. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F6868009"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 130 mg/26 mL (26 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 45 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 45 mg/0.5 mL (0.5 mL); 90 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F6867211"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321916"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Stelara Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">130MG/26ML (per mL): $88.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Stelara Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg/0.5 mL (per 0.5 mL): $15,910.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Stelara Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg/0.5 mL (per 0.5 mL): $15,910.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg/mL (per mL): $31,820.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869014"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 130 mg/26 mL (26 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 45 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stelara: 90 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614291"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Vials (5 mg/mL) must be diluted prior to administration. Infuse over at least 1 hour; use an IV set with an in-line, low-protein binding filter (0.2 micrometer). Do not infuse concomitantly in the same IV line with other agents; based on adult recommendations and pediatric (age ≥12 years) trial experience which utilized adult dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31058718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31058718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Appropriate dosage form dependent on patient weight:</p>
<p style="text-indent:-2em;margin-left:4em;">Weight &lt;60 kg: Single-dose vial (45 mg/0.5 mL) using a 1 mL syringe with a 27-gauge, <sup>1</sup>/<sub>2</sub>-inch needle.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight ≥60 kg: Prefilled syringes may be used.</p>
<p style="text-indent:-2em;margin-left:4em;">Administer by SUBQ injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Pediatric patients should have doses administered by a health care professional.</p></div>
<div class="block adm drugH1Div" id="F6868005"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over at least 1 hour; use of IV set with an in-line, low-protein binding filter (0.2 micrometer) required. Do not infuse concomitantly in the same IV line with other agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician; self-injection may occur after proper training. If using the single-dose vial, a 1 mL syringe with a 27-gauge <sup>1</sup>/<sub>2</sub> inch needle is recommended.</p></div>
<div class="block sts drugH1Div" id="F6867990"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials and prefilled syringes at 2°C to 8°C (36°F to 46°F); do not freeze. Store vials upright in the original carton to protect from light until the time of use. Do not shake. Discard any unused portion. Individual prefilled syringes may be stored at room temperature (&lt;30°C [&lt;86°F]) for ≤30 days in the original carton to protect from light; once stored at room temperature, syringe should not be returned to the refrigerator and discarded if not used within 30 days. Diluted solution for infusion may be stored up to 7 hours at room temperature (up to 25°C [77°F]). Infusion should be completed within 8 hours of preparation (including the storage and infusion times); do not freeze diluted solutions.</p></div>
<div class="block meg drugH1Div" id="F9419531"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Stelara: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125261s158%2C761044s009lbl.pdf%23page%3D36&amp;token=V3%2FJ3vdg%2FBSdfJhpw01C8Llmb1Jknd4nk%2FA92oskHyal3xQlljGF8GHU1032se94NFt8aUfiqtQs%2FnKr0st1LAv%2FZCw%2FHjvEjrRCzTiR31C8nxZTP634omSzpqV73axQ&amp;TOPIC_ID=126474" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125261s158,761044s009lbl.pdf#page=36</a></p>
<p style="text-indent:-2em;margin-left:4em;">Wezlana: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761285s000%2C761331s000lbl.pdf%23page%3D36&amp;token=HeeZLnl2kLIXZci0dWY%2FsE9BAjw%2BMAMqrfxTktvqVmXuqKXnfKuD7isOiIdqWKZln%2F%2F10l2SQJ%2FDbC83mVAGV3NwKjS1uFgAYjFz8H%2F47pR6F7ZIwL9%2F7GPvdluE8mlw&amp;TOPIC_ID=126474" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761285s000,761331s000lbl.pdf#page=36</a></p></div>
<div class="block usep drugH1Div" id="F53570342"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy (FDA approved in ages ≥6 years and adults); treatment of active psoriatic arthritis (FDA approved in ages ≥6 years and adults); treatment of moderately to severely active Crohn disease (FDA approved in adults); treatment of moderate to severe active ulcerative colitis (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F6867207"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Stelara may be confused with Aldara</p>
<p style="text-indent:-2em;margin-left:4em;">Ustekinumab may be confused with infliximab, rituximab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300199"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6872026"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Anti-Psoriasis Agents may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Ustekinumab may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of infection may be increased. Ustekinumab may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Ustekinumab may decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">InFLIXimab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53688080"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients treated for plaque psoriasis are encouraged to use contraception during therapy. Based on available data, agents other than ustekinumab may be preferred for use in patients planning to conceive (Yeung 2020). The American Academy of Dermatology considers ustekinumab for the treatment of psoriasis to be acceptable for use in patients planning to father a child (AAD/NPF [Menter 2019]). Females and males with well-controlled psoriasis who are planning a pregnancy and wish to avoid fetal exposure can consider discontinuing ustekinumab 15 weeks prior to attempting pregnancy (Rademaker 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes; maternal disease and serum levels of biologic therapy should be optimized prior to conception. Biologics, such as ustekinumab, may be continued in patients with inflammatory bowel disease planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited data, use of ustekinumab may be continued through conception in patients with rheumatic and musculoskeletal diseases who are planning a pregnancy and not able to use alternative therapies; use should be discontinued once pregnancy is confirmed. Conception should be planned during a period of quiescent/low disease activity. Recommendations for use of ustekinumab to treat rheumatic and musculoskeletal diseases in patients who are planning to father a child are not available due to limited data (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F6867269"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ustekinumab crosses the placenta (Klenske 2019; Mitrova 2021; Mitrova 2022; Rowan 2018; Saito 2022; Sako 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Ustekinumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">In pregnant patients with inflammatory bowel disease (IBD), cord blood concentrations of ustekinumab are higher than maternal trough levels at delivery. In most cases, ustekinumab was continued into the third trimester. Cord blood concentrations were lower in some cases when maternal treatment was stopped during the second trimester but may correlate better with maternal blood concentrations than the time of the last dose (Klenske 2019; Mitrova 2021; Mitrova 2022; Rowan 2018; Saito 2022; Sako 2021). The clearance of ustekinumab from the newborn circulation was evaluated in 9 infants of mothers treated for IBD; the time to clearance was 6 to 19 weeks (complete data not available for 7 additional infants) (Flanagan 2022). In 1 case report, ustekinumab was detected in cord blood at delivery (38 weeks' gestation; last maternal dose 23 weeks' gestation) but not in neonatal blood when sampled 6 months postpartum (Sako 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Based on maternal trough concentrations, pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of ustekinumab in a clinically significant way (Flanagan 2022; Rowan 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of ustekinumab during pregnancy are becoming available from registries and prospective studies (Abraham 2022; Dernoncourt 2022; Echeverría-García 2017; Ghalandari 2022; Mahadevan 2022; Mitrova 2022); however, current guidance considers the available data related to the use of ustekinumab in pregnancy to be limited (ECCO [Torres 2023]; Lamb 2019; Mahadevan 2019; Yeung 2020).</p>
<p style="text-indent:0em;margin-top:2em;">The American Academy of Dermatology considers the safety of ustekinumab for the treatment of psoriasis in pregnancy to be uncertain (AAD/NPF [Menter 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Until additional data are available, ustekinumab is not currently recommended for the treatment of rheumatic and musculoskeletal diseases during pregnancy. Ustekinumab should be discontinued once pregnancy is confirmed (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">IBD is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. When treatment for inflammatory bowel disease is needed in pregnant patients, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For ustekinumab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery (4 to 5 weeks before delivery if every-4-week dosing), then continued 48 hours' postpartum (Mahadevan 2019).</p></div>
<div class="block mopp drugH1Div" id="F53570341"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prior to and during therapy as appropriate</i>: Tuberculosis screening (prior to initiating and periodically during therapy); hepatitis C virus/hepatitis B virus (HBV) screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); HIV screening (baseline) (AAD/NPF [Menter 2019].</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>During therapy</i>: Monitor for infusion reactions, CBC with differential (baseline), complete metabolic panel (baseline); ustekinumab-antibody formation; monitor for signs/symptoms of infection, reversible posterior leukoencephalopathy syndrome, and squamous cell skin carcinoma.</p></div>
<div class="block pha drugH1Div" id="F6868003"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ustekinumab is a human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin (IL)-12 and IL-23. Biological effects of IL-12 and IL-23 include natural killer (NK) cell activation, CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), interferon-inducible protein-10 (IP-10), and interleukin-8 (IL-8). Significant clinical improvement in psoriasis and psoriatic arthritis patients is seen in association with reduction of these proinflammatory signalers.</p></div>
<div class="block phk drugH1Div" id="F6867991"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Psoriasis: Response best determined after 12 weeks (AAD/NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Crohn disease: V<sub>d</sub> (central compartment): 2.7 L; V<sub>dss</sub>: 4.6 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Ulcerative colitis: V<sub>d</sub> (central compartment): 3 L; V<sub>dss</sub>: 4.4 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Crohn disease, ulcerative colitis: Terminal: ~19 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Psoriasis: 14.9 ± 4.6 to 45.6 ± 80.2 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Psoriasis: SubQ: 45 mg: 13.5 days; 90 mg: 7 days.</p></div>
<div class="block phksp drugH1Div" id="F51204416"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: When given the same dose, subjects weighing &gt;100 kg had lower median serum concentrations compared with those subjects weighing ≤100 kg. The median trough serum concentrations of ustekinumab in subjects &gt;100 kg in the 90 mg group were comparable with those in subjects ≤100 kg in the 45 mg group.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961946"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Stelara</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36777422">
<a name="36777422"></a>Abraham BP, Ott E, Busse C, et al. Ustekinumab exposure in pregnant women from inflammatory bowel disease clinical trials: pregnancy outcomes through up to 5 years in Crohn's disease and 2 years in ulcerative colitis. <i>Crohns Colitis 360</i>. 2022;4(3):otac025. doi:10.1093/crocol/otac025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36777422/pubmed" id="36777422" target="_blank">36777422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36369405">
<a name="36369405"></a>Ak T, Durmus RB, Onel M. Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature. <i>Clin Rheumatol</i>. 2023;42(2):339-357. doi:10.1007/s10067-022-06406-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36369405/pubmed" id="36369405" target="_blank">36369405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AlHashash.1">
<a name="AlHashash.1"></a>Al Hashash J. Medical management of moderate to severe Crohn disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 21, 2023. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30872149">
<a name="30872149"></a>Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. <i>J Am Acad Dermatol</i>. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30872149/pubmed" id="30872149" target="_blank">30872149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Rheumatology (ACR). Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases guideline summary. Published August 3, 2022. Accessed August 16, 2022. https://www.rheumatology.org/Portals/0/Files/Vaccinations-Guidance-Summary.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33386732">
<a name="33386732"></a>Bar-Gil Shitrit A, Ben-Horin S, Mishael T, et al. Detection of ustekinumab in breast milk of nursing mothers with Crohn disease. <i>Inflamm Bowel Dis</i>. 2021;27(5):742-745. doi:10.1093/ibd/izaa325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33386732/pubmed" id="33386732" target="_blank">33386732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26854655">
<a name="26854655"></a>Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in pediatric crohn disease patients. <i>J Pediatr Gastroenterol Nutr</i>. 2016;63(3):348-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/26854655/pubmed" id="26854655" target="_blank">26854655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26641739">
<a name="26641739"></a>Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. <i>Br J Dermatol</i>. 2016;174(4):839-846. doi:10.1111/bjd.14338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/26641739/pubmed" id="26641739" target="_blank">26641739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30540343">
<a name="30540343"></a>Brinker A, Cheng C, Chan V. Association of noninfectious pneumonia with ustekinumab use. <i>JAMA Dermatol</i>. 2019;155(2):221-224. doi:10.1001/jamadermatol.2018.4118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30540343/pubmed" id="30540343" target="_blank">30540343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33737254">
<a name="33737254"></a>Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(8):2968-2982. doi:10.1016/j.jaip.2021.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33737254/pubmed" id="33737254" target="_blank">33737254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33860795">
<a name="33860795"></a>Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. <i>J Crohns Colitis</i>. 2021;15(11):1846-1851. doi:10.1093/ecco-jcc/jjab070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33860795/pubmed" id="33860795" target="_blank">33860795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31866266">
<a name="31866266"></a>Cho SI, Kang S, Kim YE, Lee JY, Jo SJ. Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea.<i> J Am Acad Dermatol</i>. 2020;82(5):1243-1245. doi:10.1016/j.jaad.2019.12.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31866266/pubmed" id="31866266" target="_blank">31866266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35411727">
<a name="35411727"></a>Choi MG, Ye BD, Yang SK, Shim TS, Jo KW, Park SH. The risk of tuberculosis in patients with inflammatory bowel disease treated with vedolizumab or ustekinumab in Korea. <i>J Korean Med Sci</i>. 2022;37(14):e107. doi:10.3346/jkms.2022.37.e107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35411727/pubmed" id="35411727" target="_blank">35411727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36068977">
<a name="36068977"></a>Chou YJ, Wu CY, Pan TY, Wu CY, Chang YT. Risk of malignancy in patients with psoriasis receiving systemic medications: A nested case-control study. <i>Dermatol Ther</i>. 2022;35(11):e15804. doi:10.1111/dth.15804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36068977/pubmed" id="36068977" target="_blank">36068977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34720823">
<a name="34720823"></a>Cohen B, Tomer G, Gavrilova T. Successful drug desensitization to ustekinumab in a patient with Crohn's Disease. <i>Case Rep Gastroenterol</i>. 2021;15(2):657-661. doi:10.1159/000516318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34720823/pubmed" id="34720823" target="_blank">34720823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohen.1">
<a name="Cohen.1"></a>Cohen RD, Stein AC. Management of moderate to severe ulcerative colitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 12, 2023. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33016326">
<a name="33016326"></a>Crosby S, Schuh MJ, Farraye FA. Rechallenge with subcutaneous ustekinumab after hypersensitivity reaction to intravenous ustekinumab. <i>J Crohns Colitis</i>. 2021;15(5):871. doi:10.1093/ecco-jcc/jjaa202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33016326/pubmed" id="33016326" target="_blank">33016326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33775893">
<a name="33775893"></a>Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study. <i>Clin Gastroenterol Hepatol</i>. 2022;20(10):2399-2401.e4. doi:10.1016/j.cgh.2021.03.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33775893/pubmed" id="33775893" target="_blank">33775893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31058718">
<a name="31058718"></a>Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. <i>J Pediatr Gastroenterol Nutr</i>. 2019;69(1):61-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31058718/pubmed" id="31058718" target="_blank">31058718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401769">
<a name="36401769"></a>Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase). <i>BioDrugs</i>. 2022:1–15. doi:10.1007/s40259-022-00564-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36401769/pubmed" id="36401769" target="_blank">36401769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35854305">
<a name="35854305"></a>Despotes KA, Vigeland CL. Stelara struck: a case of noninfectious pneumonitis secondary to ustekinumab. <i>BMC Pulm Med</i>. 2022;22(1):280. doi:10.1186/s12890-022-02066-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35854305/pubmed" id="35854305" target="_blank">35854305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27765165">
<a name="27765165"></a>Echeverría-García B, Nuño-González A, Dauden E, et al; Grupo de estudio BIOBADADERM. A case series of patients with psoriasis exposed to biologic therapy during pregnancy: the BIOBADADERM register and a review of the literature.<i> Actas Dermosifiliogr.</i> 2017;108(2):168-170. English, Spanish. doi:10.1016/j.ad.2016.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/27765165/pubmed" id="27765165" target="_blank">27765165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959607">
<a name="27959607"></a>Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. <i>N Engl J Med</i>. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/27959607/pubmed" id="27959607" target="_blank">27959607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36212052">
<a name="36212052"></a>Feng Y, Zhou B, Wang Z, et al. Risk of <i>Candida</i> infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: A systematic review and meta-analysis of randomized controlled trials. <i>Int J Clin Pract</i>. 2022;2022:2442603. doi:10.1155/2022/2442603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36212052/pubmed" id="36212052" target="_blank">36212052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780013">
<a name="28780013"></a>Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/28780013/pubmed" id="28780013" target="_blank">28780013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28893407">
<a name="28893407"></a>Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. <i>J Am Acad Dermatol</i>. 2017;77(5):845-854.e5. doi:10.1016/j.jaad.2017.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/28893407/pubmed" id="28893407" target="_blank">28893407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34907546">
<a name="34907546"></a>Flanagan E, Prentice R, Wright EK, et al. Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. <i>Aliment</i>
<i>Pharmacol Ther</i>. 2022;55(6):700-704. doi:10.1111/apt.16739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34907546/pubmed" id="34907546" target="_blank">34907546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fleshner.1">
<a name="Fleshner.1"></a>Fleshner PR. Surgical management of Crohn disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 21, 2023. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23442134">
<a name="23442134"></a>Galvan-Banqueri M, Marin Gil R, Santos Ramos, B, et al. Biological Treatments for Moderate-to-Severe Psoriasis: Indirect Comparison. <i>J Clin Pharm Ther</i>. 2013;38(2):121-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23442134/pubmed" id="23442134" target="_blank">23442134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35894810">
<a name="35894810"></a>Ghalandari N, Crijns HJMJ, Bergman JEH, Dolhain RJEM, van Puijenbroek EP, Hazes JMW. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance.<i> Br J Clin Pharmacol.</i> 2022;88(12):5378-5388. doi:10.1111/bcp.15471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35894810/pubmed" id="35894810" target="_blank">35894810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21978572">
<a name="21978572"></a>Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.<i> J Am Acad Dermatol</i>. 2012;66(5):742-751. doi:10.1016/j.jaad.2011.06.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/21978572/pubmed" id="21978572" target="_blank">21978572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33294551">
<a name="33294551"></a>Hafez DM, Alshehri N, Alshehri H, Al-Dawsari NA. Ustekinumab-induced fixed drug eruption. <i>JAAD Case Rep</i>. 2020;6(12):1234-1235. doi:10.1016/j.jdcr.2020.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33294551/pubmed" id="33294551" target="_blank">33294551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33133239">
<a name="33133239"></a>Haider SA, Yadav A, Perry C, et al. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. <i>Therap Adv Gastroenterol</i>. 2020;13:1756284820959245. doi:10.1177/1756284820959245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33133239/pubmed" id="33133239" target="_blank">33133239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35191100">
<a name="35191100"></a>Hasan B, Tandon KS, Miret R, et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. <i>J Gastroenterol Hepatol</i>. 2022;37(6):1016-1021. doi: 10.1111/jgh.15806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35191100/pubmed" id="35191100" target="_blank">35191100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35254749">
<a name="35254749"></a>Hollywood A, Murray G, Fleming S, Kirby B, Hughes R. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. <i>J Drugs Dermatol</i>. 2022;21(3):319-320. doi:10.36849/JDD.6298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35254749/pubmed" id="35254749" target="_blank">35254749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35262671">
<a name="35262671"></a>Hong SJ, Zenger C, Pecoriello J, et al. Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy.<i> Inflamm Bowel Dis</i>. 2022;28(12):1826-1832. doi:10.1093/ibd/izac035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35262671/pubmed" id="35262671" target="_blank">35262671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35694729">
<a name="35694729"></a>Husein-ElAhmed H, Steinhoff M. Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. <i>J Dermatolog Treat</i>. 2022;33(7):2886-2893. doi:10.1080/09546634.2022.2089331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35694729/pubmed" id="35694729" target="_blank">35694729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35192196">
<a name="35192196"></a>Jiang SW, Kwock JT, Liu B, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. <i>Br J Dermatol</i>. 2022;187(3):417-419. doi:10.1111/bjd.21066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35192196/pubmed" id="35192196" target="_blank">35192196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36191274">
<a name="36191274"></a>Johnson AM, Barsky M, Ahmed W, et al. The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium. <i>Am J Gastroenterol</i>. 2023;118(2):317-328. doi:10.14309/ajg.0000000000002047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36191274/pubmed" id="36191274" target="_blank">36191274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36212237">
<a name="36212237"></a>Jordan A, Kinnucan J. Ustekinumab-associated posterior reversible encephalopathy syndrome in a patient with Crohn's Disease. <i>ACG Case Rep J</i>. 2022;9(10):e00867. doi:10.14309/crj.0000000000000867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36212237/pubmed" id="36212237" target="_blank">36212237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32962463">
<a name="32962463"></a>Kalra SS, Chizinga M, Trillo-Alvarez C, Papierniak ES. Ustekinumab associated chronic eosinophilic pneumonia. <i>J Asthma</i>. 2021;58(12):1670-1674. doi:10.1080/02770903.2020.1827416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32962463/pubmed" id="32962463" target="_blank">32962463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34309516">
<a name="34309516"></a>Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, Stratigos AJ, Sfikakis PP. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. <i>Eur J Dermatol</i>. 2021;31(3):307-317. doi:10.1684/ejd.2021.4056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34309516/pubmed" id="34309516" target="_blank">34309516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23279003">
<a name="23279003"></a>Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>J Eur Acad Dermatol Venereol</i>. 2013;27(12):1535-1545. doi:10.1111/jdv.12046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23279003/pubmed" id="23279003" target="_blank">23279003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30388211">
<a name="30388211"></a>Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease. <i>J Crohns Colitis</i>. 2019;13(2):267-269. doi:10.1093/ecco-jcc/jjy153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30388211/pubmed" id="30388211" target="_blank">30388211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34939919">
<a name="34939919"></a>Kremenevski I, Sander O, Sticherling M, Raithel M, LastName FM. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. <i>Dtsch Arztebl Int</i>. 2022;119(6):88-95. doi:10.3238/arztebl.m2022.0067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34939919/pubmed" id="34939919" target="_blank">34939919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32904020">
<a name="32904020"></a>Krugliak Cleveland N, Masching A, Rubin DT. Hypersensitivity to IV ustekinumab but tolerance to subcutaneous ustekinumab in a patient with Crohn's Disease. <i>ACG Case Rep J</i>. 2020;7(8):e00449. doi:10.14309/crj.0000000000000449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32904020/pubmed" id="32904020" target="_blank">32904020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562236">
<a name="31562236"></a>Lamb CA, Kennedy NA, Raine T, et al; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i>. 2019;68(suppl 3):S1-S106. doi:10.1136/gutjnl-2019-318484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31562236/pubmed" id="31562236" target="_blank">31562236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26259989">
<a name="26259989"></a>Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. <i>J Am Acad Dermatol</i>. 2015;73(4):594-603. doi:10.1016/j.jaad.2015.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/26259989/pubmed" id="26259989" target="_blank">26259989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18486739">
<a name="18486739"></a>Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1). <i>Lancet</i>. 2008;371(9625):1665-1674. doi:10.1016/S0140-6736(08)60725-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/18486739/pubmed" id="18486739" target="_blank">18486739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23192911">
<a name="23192911"></a>Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. <i>Rheumatology (Oxford)</i>. 2013;52(1):53-61. doi:10.1093/rheumatology/kes305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23192911/pubmed" id="23192911" target="_blank">23192911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36880432">
<a name="36880432"></a>Liu R, Li Z, Ye L, et al. Risk of tuberculosis and hepatitis B reactivation in patients with Crohn's Disease on ustekinumab: A nationwide real-world study.<i> Inflamm Bowel Dis</i>. 2023:izad032. doi:10.1093/ibd/izad032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36880432/pubmed" id="36880432" target="_blank">36880432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32283057">
<a name="32283057"></a>Loeff FC, Tsakok T, Dijk L, et al. Clinical impact of antibodies against ustekinumab in psoriasis: an observational, cross-sectional, multicenter study. <i>J Invest Dermatol</i>. 2020;140(11):2129-2137. doi:10.1016/j.jid.2020.03.957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32283057/pubmed" id="32283057" target="_blank">32283057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35560249">
<a name="35560249"></a>Mahadevan U, Naureckas S, Tikhonov I, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: review of cases reported to the manufacturer's global safety database. <i>Aliment Pharmacol Ther</i>. 2022;56(3):477-490. doi:10.1111/apt.16960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35560249/pubmed" id="35560249" target="_blank">35560249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29857090">
<a name="29857090"></a>Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. <i>Gastroenterology</i>. 2018;155(3):696-704. doi:10.1053/j.gastro.2018.05.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/29857090/pubmed" id="29857090" target="_blank">29857090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30772098">
<a name="30772098"></a>Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.<i> J Am Acad Dermatol</i>. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30772098/pubmed" id="30772098" target="_blank">30772098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34628078">
<a name="34628078"></a>Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of reinduction and/or dose escalation of ustekinumab in Crohn's disease: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2022;20(12):2728-2740.e1. doi:10.1016/j.cgh.2021.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34628078/pubmed" id="34628078" target="_blank">34628078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35708729">
<a name="35708729"></a>Mitrova K, Pipek B, Bortlik M, et al; Czech IBD Working Group. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study.<i> J Crohns Colitis</i>. 2022;16(12):1808-1815. doi:10.1093/ecco-jcc/jjac086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35708729/pubmed" id="35708729" target="_blank">35708729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34394725">
<a name="34394725"></a>Mitrova K, Pipek B, Bortlik M, et al. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. <i>Therap Adv Gastroenterol.</i> 2021;14:17562848211032790. doi:10.1177/17562848211032790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34394725/pubmed" id="34394725" target="_blank">34394725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32279593">
<a name="32279593"></a>Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, Vega-Gutiérrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. <i>J Dermatolog Treat</i>. 2022;33(1):348-353. doi:10.1080/09546634.2020.1755008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32279593/pubmed" id="32279593" target="_blank">32279593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33307146">
<a name="33307146"></a>Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. <i>J Am Acad Dermatol</i>. 2022;86(5):1080-1091. doi:10.1016/j.jaad.2020.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33307146/pubmed" id="33307146" target="_blank">33307146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349983">
<a name="33349983"></a>Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations.<i> J Eur Acad Dermatol Venereol</i>. 2020;34(11):2461-2498. doi:10.1111/jdv.16915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33349983/pubmed" id="33349983" target="_blank">33349983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109634">
<a name="32109634"></a>Ollech JE, Normatov I, Peleg N, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn's disease. <i>Clin Gastroenterol Hepatol</i>. 2021;19(1):104-110. doi:10.1016/j.cgh.2020.02.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32109634/pubmed" id="32109634" target="_blank">32109634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36930430">
<a name="36930430"></a>Panaccione R, Lee WJ, Clark R, et al. Dose escalation patterns of advanced therapies in Crohn's disease and ulcerative colitis: a systematic literature review. <i>Adv Ther</i>. 2023;40(5):2051-2081. doi:10.1007/s12325-023-02457-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36930430/pubmed" id="36930430" target="_blank">36930430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33086438">
<a name="33086438"></a>Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. <i>Aliment Pharmacol Ther</i>. 2020;52(11-12):1658-1675. doi:10.1111/apt.16119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/33086438/pubmed" id="33086438" target="_blank">33086438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23301632">
<a name="23301632"></a>Papp KA, Griffiths CE, Gordon K, et al; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>Br J Dermatol</i>. 2013;168(4):844-54. doi:10.1111/bjd.12214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23301632/pubmed" id="23301632" target="_blank">23301632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18486740">
<a name="18486740"></a>Papp KA, Langley RG, Lebwohl M, et al. Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). <i>Lancet</i>. 2008;371(9625):1675-1684. doi:10.1016/S0140-6736(08)60726-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/18486740/pubmed" id="18486740" target="_blank">18486740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911203">
<a name="22911203"></a>Pernet C, Guillot B, Bessis D. Eczematous drug eruption after ustekinumab treatment. <i>Arch Dermatol</i>. 2012;148(8):959-960. doi:10.1001/archdermatol.2012.586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/22911203/pubmed" id="22911203" target="_blank">22911203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28110056">
<a name="28110056"></a>Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):600-609. doi:10.1016/j.jaip.2016.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/28110056/pubmed" id="28110056" target="_blank">28110056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100. doi:10.1111/ajd.12641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761156">
<a name="17761156"></a>Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and Il-2Rα Expression and Inhibition of IL-12- and IL-23-Induced Cytokine Secretion by CNTO 1275. <i>Cell Immunol</i>. 2007;247(1):1-11. doi:10.1016/j.cellimm.2007.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/17761156/pubmed" id="17761156" target="_blank">17761156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37240501">
<a name="37240501"></a>Roblin X, Duru G, Papamichael K, et al. Development of antibodies to ustekinumab is associated with loss of response in patients with inflammatory bowel disease. <i>J Clin Med</i>. 2023;12(10):3395. doi:10.3390/jcm12103395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/37240501/pubmed" id="37240501" target="_blank">37240501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31288233">
<a name="31288233"></a>Romaní J, Vilarrasa E, Martorell A, Fuertes I, Ciudad C, Molina-Leyva A. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. <i>Dermatology</i>. 2020;236(1):21-24. doi:10.1159/000501075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31288233/pubmed" id="31288233" target="_blank">31288233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045603">
<a name="29045603"></a>Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's disease treated until 33 weeks of gestation. <i>J Crohns Colitis</i>. 2018;12(3):376-378. doi:10.1093/ecco-jcc/jjx141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/29045603/pubmed" id="29045603" target="_blank">29045603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35773736">
<a name="35773736"></a>Saito J, Kaneko K, Kawasaki H, et al. Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. <i>J Pharm Health Care Sci</i>. 2022;8(1):18. doi:10.1186/s40780-022-00249-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35773736/pubmed" id="35773736" target="_blank">35773736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34746508">
<a name="34746508"></a>Sako M, Yoshimura N, Sonoda A, et al. Safety prediction of infants born to mothers with Crohn's disease treated with biological agents in the late gestation period.<i> J Anus Rectum Colon</i>. 2021;5(4):426-432. doi:10.23922/jarc.2021-021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34746508/pubmed" id="34746508" target="_blank">34746508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37200724">
<a name="37200724"></a>Samalik J, Adler J, Singer AAM. Letter to the editor in response to: Hypersensitivity reaction to ustekinumab in pediatric and young adult inflammatory bowel disease patients: A Case Series. <i>JPGN Rep</i>. 2023;4(2):e293. doi:10.1097/PG9.0000000000000293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/37200724/pubmed" id="37200724" target="_blank">37200724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32700796">
<a name="32700796"></a>Sánchez-Martínez EM, García-Ruiz R, Moneva-Léniz LM, Mateu-Puchades A. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. <i>Dermatol Ther</i>. 2020;33(6):e14054. doi:10.1111/dth.14054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32700796/pubmed" id="32700796" target="_blank">32700796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32964215">
<a name="32964215"></a>Sandborn WJ, Feagan BG, Danese S, et al. Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis of results from phase 2/3 studies. <i>Inflamm Bowel Dis</i>. 2021;27(7):994-1007. doi:10.1093/ibd/izaa236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32964215/pubmed" id="32964215" target="_blank">32964215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23075178">
<a name="23075178"></a>Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. <i>N Engl J Med</i>. 2012;367(16):1519-1528. doi:10.1056/NEJMoa1203572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23075178/pubmed" id="23075178" target="_blank">23075178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35691323">
<a name="35691323"></a>Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet</i>. 2022;399(10342):2200-2211. doi:10.1016/S0140-6736(22)00688-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35691323/pubmed" id="35691323" target="_blank">35691323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35237349">
<a name="35237349"></a>Sarto J, Caballol B, Berenguer J, et al. Clinically reversible ustekinumab-induced encephalopathy: Case report and review of the literature. <i>Ther Adv Neurol Disord</i>. 2022;15:17562864221079682. doi:10.1177/17562864221079682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35237349/pubmed" id="35237349" target="_blank">35237349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541488">
<a name="28541488"></a>Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12/23 in T cell-related chronic inflammation: Implications of immunodeficiency and therapeutic blockade. <i>Rheumatology (Oxford)</i>. 2018;57(2):246-254. doi:10.1093/rheumatology/kex186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/28541488/pubmed" id="28541488" target="_blank">28541488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35604382">
<a name="35604382"></a>Shehab M, Alrashed F, Heron V, Restellini S, Bessissow T. Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn's disease: systematic review and network meta-analysis of randomized controlled trials. <i>Inflamm Bowel Dis</i>. 2023;29(3):367-375. doi:10.1093/ibd/izac103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35604382/pubmed" id="35604382" target="_blank">35604382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34688373">
<a name="34688373"></a>Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. <i>Lancet Gastroenterol Hepatol</i>. 2021;6(12):1002-1014. doi:10.1016/S2468-1253(21)00312-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/34688373/pubmed" id="34688373" target="_blank">34688373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32975344">
<a name="32975344"></a>Srinivas C, Odsbu I, Linder M. Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab. <i>Pharmacoepidemiol Drug Saf</i>. 2020;29(12):1562-1569. doi:10.1002/pds.5132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32975344/pubmed" id="32975344" target="_blank">32975344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stelara.1">
<a name="Stelara.1"></a>Stelara (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stelara.2">
<a name="Stelara.2"></a>Stelara (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stelara.3">
<a name="Stelara.3"></a>Stelara and Stelara IV (ustekinumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37168900">
<a name="37168900"></a>Sunny J, Fonseca AG, Crim AM, Goyal A, Felipez LM. Hypersensitivity reaction to ustekinumab in pediatric and young adult inflammatory bowel disease patients: A Case Series. <i>JPGN Rep</i>. 2022;3(2):e205. doi:10.1097/PG9.0000000000000205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/37168900/pubmed" id="37168900" target="_blank">37168900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35789168">
<a name="35789168"></a>Tabak GH, Akdogan N, Yel B, Gokoz O. The emergence of morphea in a patient undergoing ustekinumab therapy given for psoriasis. <i>Dermatol Ther</i>. 2022;35(9):e15687. doi:10.1111/dth.15687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35789168/pubmed" id="35789168" target="_blank">35789168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31638283">
<a name="31638283"></a>Takeda K, Kikuchi K, Kanazawa Y, Yamasaki K, Aiba S. Ustekinumab treatment for hidradenitis suppurativa. <i>J Dermatol</i>. 2019;46(12):1215-1218. doi:10.1111/1346-8138.15122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31638283/pubmed" id="31638283" target="_blank">31638283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163‐172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32588044">
<a name="32588044"></a>Thomas PW, Ferwerda G, West RL, Hoentjen F. Immediate infusion reaction to intravenous ustekinumab in three Crohn's Disease patients: A case report and review of the literature. <i>J Crohns Colitis</i>. 2021;15(1):162-164. doi:10.1093/ecco-jcc/jjaa115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32588044/pubmed" id="32588044" target="_blank">32588044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36005814">
<a name="36005814"></a>Torres J, Chaparro M, Julsgaard M, et al. European Crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation. <i>J Crohns Colitis</i>. 2023;17(1):1-27. doi:10.1093/ecco-jcc/jjac115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36005814/pubmed" id="36005814" target="_blank">36005814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32502365">
<a name="32502365"></a>Valenzuela-Ubiña S, Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos ME, Linares-Barrios M. Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series. <i>J Dermatolog Treat</i>. 2022;33(2):1159-1162. doi:10.1080/09546634.2020.1776208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32502365/pubmed" id="32502365" target="_blank">32502365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36472386">
<a name="36472386"></a>van der Schoot LS, Baerveldt EM, van Enst WA, et al. National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure. <i>J Dermatolog Treat</i>. 2022;2154570. doi:10.1080/09546634.2022.2154570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/36472386/pubmed" id="36472386" target="_blank">36472386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35860015">
<a name="35860015"></a>Wang J, Geng X, Zhang X, Xiao Y, Wang W. Hepatitis B virus reactivation and mycobacterial infections associated with ustekinumab: A retrospective study of an international pharmacovigilance database. <i>Front Pharmacol</i>. 2022;13:921084. doi:10.3389/fphar.2022.921084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/35860015/pubmed" id="35860015" target="_blank">35860015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis.</i> 2019;25(2):328-335. doi:10.1093/ibd/izy333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23728153">
<a name="23728153"></a>Yashiro M, Maejima H, Taniguchi T, Katsuoka K, Kimura M, Wada M. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment. <i>Eur J Dermatol</i>. 2013;23(3):396-397. doi:10.1684/ejd.2013.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/23728153/pubmed" id="23728153" target="_blank">23728153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32500730">
<a name="32500730"></a>Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper. <i>J Cutan Med Surg</i>. 2020;24(suppl 1):S3-S14. doi:10.1177/1203475420928376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ustekinumab-including-biosimilars-pediatric-drug-information/abstract-text/32500730/pubmed" id="32500730" target="_blank">32500730</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126474 Version 110.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
